Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $6.67.

A number of equities analysts have recently weighed in on IPHA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Innate Pharma in a research note on Tuesday, September 22nd. BTIG Research restated a “buy” rating and issued a $9.00 price objective on shares of Innate Pharma in a research note on Thursday, September 17th. HC Wainwright reaffirmed a “buy” rating on shares of Innate Pharma in a research report on Monday, September 21st. UBS Group reiterated a “buy” rating on shares of Innate Pharma in a research note on Tuesday, August 11th. Finally, Leerink Partners raised shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a report on Tuesday, August 11th.

Innate Pharma Stock Performance

Innate Pharma stock opened at $1.59 on Wednesday. Innate Pharma has a fifty-two week low of $1.17 and a fifty-two week high of $2.71. The firm’s 50-day simple moving average is $1.95 and its 200 day simple moving average is $1.76.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune cells that can recognize and attack tumors. Its product candidates include monoclonal antibodies, immune-cell engagers and other treatments designed to stimulate or direct immune responses against cancer.

Innate Pharma’s pipeline has included lacutamab, an antibody targeting KIR3DL2 for the treatment of certain T-cell lymphomas, including cutaneous T-cell lymphoma.